Caxton Associates (New York)’s Regeneron Pharmaceuticals REGN Stock Holding History

Caxton Associates (New York)’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	$454K	Buy	637 +49	+8%	+$41.1K	0.01%	350
2024 Q3	$618K	Sell	588 -562	-49%	-$625K	0.02%	329
2024 Q2	$1.21M	Buy	+1,150	New	+$1.11M	0.04%	221
2024 Q1	–	Sell	-10,000	Closed	-$8.78M	–	566
2023 Q4	$8.78M	Buy	+10,000	New	+$8.23M	0.45%	54
2020 Q4	–	Sell	-897	Closed	-$502K	–	293
2020 Q3	$502K	Buy	897 +397	+79%	+$241K	0.05%	114
2020 Q2	$312K	Sell	500 -1,476	-75%	-$838K	0.03%	246
2020 Q1	$965K	Buy	+1,976	New	+$815K	0.18%	65
2019 Q2	–	Sell	-567	Closed	-$233K	–	505
2019 Q1	$233K	Buy	+567	New	+$233K	0.03%	308
2018 Q2	–	Sell	-1,944	Closed	-$669K	–	464
2018 Q1	$669K	Buy	+1,944	New	+$676K	0.03%	237
2017 Q4	–	Sell	-600	Closed	-$268K	–	497
2017 Q3	$268K	Buy	+600	New	+$286K	0.01%	448

Other funds holding REGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Caxton Associates (New York)'s REGN Position: Q4 2024 in Review

Caxton Associates (New York) increased its Regeneron Pharmaceuticals (REGN) stake by 8.3% in Q4 2024, buying an estimated $41.1K and bringing the position to 637 shares worth $454K. The position accounts for 0.01% of the portfolio, ranked #350.

Caxton Associates (New York) first reported a position in REGN in Q3 2017 and has held it in 10 quarters since. The position peaked at $8.78M in Q4 2023. 1,317 funds tracked by Wall St. Rank hold REGN as of Q4 2024.

Caxton Associates (New York) held 637 shares of Regeneron Pharmaceuticals worth $454K as of Q4 2024.
Caxton Associates (New York) bought 49 Regeneron Pharmaceuticals shares in Q4 2024, an estimated $41.1K.
Regeneron Pharmaceuticals made up 0.01% of Caxton Associates (New York)'s portfolio in Q4 2024, its #350 holding.
Caxton Associates (New York) first reported a position in Regeneron Pharmaceuticals in Q3 2017 and has held it in 10 quarters since.
Caxton Associates (New York)'s Regeneron Pharmaceuticals position peaked at $8.78M in Q4 2023.
1,317 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2024.

Based on Caxton Associates (New York)'s 13F filing for Q4 2024, filed 14 Feb 2025.